Detalhe da pesquisa
1.
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Cell
; 149(2): 307-21, 2012 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-22500798
2.
Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.
Annu Rev Pharmacol Toxicol
; 58: 209-229, 2018 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28934561
3.
Assessing adaptation of the cancer kinome in response to targeted therapies.
Biochem Soc Trans
; 42(4): 765-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25109955
4.
Massively parallel quantification of phenotypic heterogeneity in single-cell drug responses.
Sci Adv
; 7(38): eabf9840, 2021 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34533995
5.
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036.
NPJ Breast Cancer
; 7(1): 51, 2021 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33980863
6.
Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer.
Mol Cancer Res
; 18(11): 1685-1698, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32753473
7.
GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.
Mol Cancer Res
; 17(7): 1503-1518, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31000582
8.
Homogeneous time-resolved fluorescence resonance energy transfer assay for measurement of Phox/Bem1p (PB1) domain heterodimerization.
J Biomol Screen
; 13(5): 396-405, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18480472
9.
Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer.
Oncotarget
; 9(21): 15480-15497, 2018 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29643987
10.
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
PLoS One
; 13(6): e0197350, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29897904
11.
Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer.
Mol Cell Oncol
; 4(6): e1300622, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29209639
12.
MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition.
Cell Rep
; 18(10): 2387-2400, 2017 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28273454
13.
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.
J Am Heart Assoc
; 6(10)2017 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29051215
14.
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Cancer Discov
; 7(3): 302-321, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28108460
15.
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.
Cell Rep
; 11(3): 390-404, 2015 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25865888
16.
Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Clin Cancer Res
; 20(10): 2516-22, 2014 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24664307
17.
A RhoC biosensor reveals differences in the activation kinetics of RhoA and RhoC in migrating cells.
PLoS One
; 8(11): e79877, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24224016
18.
MicroRNA 9-3p targets ß1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.
Mol Cell Biol
; 33(11): 2260-74, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23530058
19.
SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling.
Mol Cell Biol
; 33(15): 3011-25, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23716599
20.
Pharmacologic targeting of drug-induced enhancers.
Oncoscience
; 4(5-6): 43-44, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28781985